Here are five takeaways:
1. Zimmer Biomet will not receive proceeds of the sale.
2. All of the proceedings will go to those stockholders.
3. Following the offering, Zimmer Biomet plans to buy $250 million common shares from Barclays Capital.
4. Zimmer Biomet will use the cash on hand to pay for the purchasing from the Blackstone and Goldman Sachs affiliates.
5. The company has spent nearly $165 million on repurchasing its shares this year.
More articles on devices:
Brian Ennis becomes president of Implanet America: 5 key notes
Healthmark introduces new Distal Soak
Smith & Nephew, Zimmer Biomet, Medovex & more: 20 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
